Sartorius Stedim BiotechCHIX:DIMP -0.28%84 ROC (Joel Greenblatt) % is 30.68% as of Mar. 2026, which is 36% below its 10-year median of 48.24. GuruFocus rates CHIX:DIMP with a GF Score™ of 84/100 and a GF Value™ of €207.75 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 839 Medical Devices & Instruments companies, Sartorius Stedim Biotech ranks better than 73.9% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Sartorius Stedim Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 30.68%.
The historical rank and industry rank for Sartorius Stedim Biotech's ROC (Joel Greenblatt) % or its related term are showing as below:
CHIX:DIMp'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 18.03 Med: 48.24 Max: 78.33
Current: 22.95
During the past 13 years, Sartorius Stedim Biotech's highest ROC (Joel Greenblatt) % was 78.33%. The lowest was 18.03%. And the median was 48.24%.
CHIX:DIMp's ROC (Joel Greenblatt) % is ranked better than 73.9% of 839
companies
in the Medical Devices & Instruments industry
Industry Median: 4.13
vs CHIX:DIMp: 22.95
Sartorius Stedim Biotech's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -23.20% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Sartorius Stedim Biotech ROC (Joel Greenblatt) % Related Terms
Sartorius Stedim Biotech ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Sartorius Stedim Biotech's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:DIMP vs ISRG, BDX, MDLN: ROC (Joel Greenblatt) % Comparison
For the Medical Instruments & Supplies subindustry, Sartorius Stedim Biotech's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius Stedim Biotech ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius Stedim Biotech's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Sartorius Stedim Biotech's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 30.68% mean?
Sartorius Stedim Biotech (CHIX:DIMP) has a ROC (Joel Greenblatt) % of 30.68% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Sartorius Stedim Biotech and its competitors. This is 36% below median its historical median of 48.24. Over the past decade, Sartorius Stedim Biotech's ROC (Joel Greenblatt) % has ranged from 18.03 to 78.33. According to the industry distribution chart, Sartorius Stedim Biotech ranks #219 out of 839 companies in the Medical Devices & Instruments industry, placing it in the top 26.1%.
Is Sartorius Stedim Biotech's ROC (Joel Greenblatt) % too high?
Sartorius Stedim Biotech's current ROC (Joel Greenblatt) % of 30.68% is 36% below median its 10-year median of 48.24. Over the past 10 years, this metric has ranged from a low of 18.03 to a high of 78.33. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 4.13. Sartorius Stedim Biotech's value of 30.68% is 642.9% above this industry median. Based on the distribution chart, Sartorius Stedim Biotech ranks #219 out of 839 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Sartorius Stedim Biotech has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's ROC (Joel Greenblatt) % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius Stedim Biotech ranks #219 out of 839 companies for ROC (Joel Greenblatt) %. This puts Sartorius Stedim Biotech in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 4.13. Sartorius Stedim Biotech's value of 30.68% is 642.9% above this benchmark. Historically, Sartorius Stedim Biotech's own ROC (Joel Greenblatt) % has ranged from 18.03 to 78.33 over the past decade. While the company's 10-year median is 48.24 vs. the industry median of 4.13, Sartorius Stedim Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.13, based on 839 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius Stedim Biotech's current ROC (Joel Greenblatt) % of 30.68% is 642.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Sartorius Stedim Biotech and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius Stedim Biotech's current ROC (Joel Greenblatt) % is 30.68%, which is 36% below median its own 10-year median of 48.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sartorius Stedim Biotech (CHIX:DIMP) is currently considered Modestly Undervalued. The stock's GF Value™ is €207.75, compared to a current price of €179.05 — trading 13.8% below its estimated fair value. The current ROC (Joel Greenblatt) % is 30.68%, which is 36% below median its 10-year median of 48.24 and 642.9% above the Medical Devices & Instruments industry median of 4.13. Sartorius Stedim Biotech's overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Sartorius Stedim Biotech (CHIX:DIMP), the current ROC (Joel Greenblatt) % is 30.68% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius Stedim Biotech (CHIX:DIMP) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued.
The current stock price of €179.05 is trading 13.8% below its estimated GF Value™ of €207.75.
GuruFocus considers Sartorius Stedim Biotech to be Modestly Undervalued.
Key valuation signals for CHIX:DIMP:
ROC (Joel Greenblatt) %: 30.68% (36% below median its 10-year median of 48.24)
GF Value™: €207.75 vs. price of €179.05 (13.8% below fair value)
Industry Position: 642.9% above the Medical Devices & Instruments median (#219 of 839)
No single metric tells the full story. See the CHIX:DIMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
84GF Score
Get the complete analysis for CHIX:DIMP
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DIMP has been successfully added to your 
